Editor's Corner

It doesn't take a political genius to see the writing on the wall regarding biosimilars. Our third top story today concerns a new pact to develop a biosimilar in Europe. As more of these deals take shape in Europe, they will add to the political pressure to create a regulatory pathway for generic biotech therapies in the U.S. This has become a mantra for payers in the U.S. demanding price relief, and the new Democratic majority in Congress is likely to view this in only one way.

I'm taking the rest of the week off for a Thanksgiving vacation. Associate Editor, Maureen Martino will be the report on Tuesday and Wednesday before our regular holiday break. If you have anything to send to FierceBiotech that demands immediate attention, she's your best contact. Until next Monday, have a great holiday break. - John Carroll

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.